ArticlePLoS computational biology2026
A benchmark of semi-supervised scRNA-seq integration methods in real-world scenarios.
Article in PLoS computational biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Robust semi-supervised scRNA-seq integration from virtual adversarial learning.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
- Update of
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Semi-supervised methods for single-cell RNA-seq integration promise improved batch correction and preservation of biological signal by leveraging cell-type labels. However, reported benefits and robustness of them towards imperfect cell type labels often come from overly idealized settings. Here we present, to our knowledge, the first systematic benchmark comparing leading semi-supervised methods with widely used unsupervised approaches across six diverse datasets under realistic conditions. Beyond randomly missing or erroneous labels, we examine four additional scenarios (boundary-mixed labels, batch-specific annotations, auto-generated labels and varied-granularity labels) and evaluate performance using nine established metrics. We find that although semi-supervised methods can provide benefits under perfect annotations, their robustness often degrades substantially under realistic imperfections. Only scANVI and ssSTACAS maintain stable but modest improvements over their unsupervised counterparts, and none consistently outperform the strongest unsupervised approach. These results indicate that current semi-supervised strategies offer limited practical advantage when label quality is modest uncertain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.